For healthcare providers: There have been many new developments in COVID-19 therapeutics over the last few months. The McLeod Health Outpatient COVID-19 Treatment Algorithm is a resource for identifying and prioritizing patients at the highest risk of progressing to severe disease and/or requiring hospitalization. This document includes medication dosing, clinical considerations for prescribing, and tips for accessing both oral and IV therapies across our service areas. Outpatient COVID Treatment Guidelines.
In order to receive therapy you will need a referral order from a provider.
There are now 2 options for COVID Infusion Therapy. Monoclonal antibody therapy with BEBTELOVIMAB has been approved under an FDA Emergency Use Authorization (EUA) for the treatment of COVID-19 in non-hospitalized adults with mild to moderate symptoms and who are at high risk of needing hospitalization for severe COVID-19. This requires a single 2 hour appointment to complete therapy. Antiviral therapy with REMDESIVIR has been approved by the FDA and is also shown to decrease the risk of needing hospitalization for severe COVID-19. This requires 3 consecutive daily appointments lasting approximately 3 hours each to complete therapy. REMDESIVIR will only be available if MAB is in short supply.
Patients who are unvaccinated, have severe immunosuppressive disease, are pregnant, or 75 or older are considered to be at highest risk for progression to severe COVID infection.
Other high-risk patients include patients with a body mass index (BMI) of at least 35 or a high-risk medical condition such as hypertension, cardiovascular disease, chronic lung disease, diabetes, chronic kidney disease, etc. Patients must be at least 12 years of age and at least 40 kg to qualify.
The greatest benefit to the treatment is within five days of COVID-19 symptom onset. If it has been more than 7 days since symptoms began patients are ineligible for the treatment.
Appointments for infusion are available at McLeod Regional Medical Center and McLeod Health Seacoast.
Healthcare providers may use the referral form below to begin the process of referring patients for treatment. Incomplete or illegible forms may delay prioritization, scheduling and treatment. Providers should discuss the risks and benefits of treatment to the patient prior to referring them.
If you are a healthcare provider:
COVID PRE EXPOSURE PROPHYLAXIS (EVUSHELD) REFERRAL
Evusheld, a combination of two monoclonal antibody medications (tixagevimab and cilgavimab), is now available at McLeod Regional Medical Center Department of Outpatient Infusion Services for certain high risk patients to help prevent COVID19. Patients must have a referral from a provider and meet the criteria outlined in the treatment plan.